Streetbeat News

Products Services

MU

Rosenblatt analyst Hans Mosesmann maintained a Buy rating on Micron Technology Inc (NASDAQ:MU) with a $225 price target. Mosesmann expects Micron to benefit from a significant memory cycle driven by AI demand and HBM industry ramp-up. Despite challenges in HBM supply, the analyst forecasts strong revenue growth for Micron.

Portfolio Pulse from Anusuya Lahiri

June 25, 2024 | 6:34 pm

LIT

XOM

Exxon Mobil has announced that it has no plans to expand into hard rock lithium mining or develop its own direct lithium extraction technology. Instead, the company will focus on its core competencies in subsurface fluids. However, Exxon is considering lithium expansion projects globally, according to executive Patrick Howarth.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 6:33 pm

BTCUSD

Congressman Matt Gaetz has introduced a bill to allow federal tax payments in Bitcoin, aiming to amend the Internal Revenue Code of 1986. The bill proposes a framework for the U.S. Treasury to develop a system for Bitcoin tax payments, with immediate conversion to dollars. This move could integrate digital currencies into mainstream financial operations and promote innovation.

Portfolio Pulse from Murtuza Merchant

June 25, 2024 | 6:31 pm

FDX

Recent options trading trends in FedEx (NYSE: FDX) show a balanced sentiment among investors, with significant trades in both calls and puts. The stock is currently trading at $254.15, down by 0.92%, and is approaching overbought territory. Analysts have mixed ratings with price targets ranging from $275 to $318.

Portfolio Pulse from Benzinga Insights

June 25, 2024 | 6:31 pm

ETHUSD

SPY

SEC Chair Gary Gensler declined to provide a timeline for the launch of a spot Ether ETF during the Bloomberg Invest event. This leaves the market uncertain about the future of such financial products.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 6:26 pm

ETHUSD

SEC Chair Gary Gensler stated that the approval process for a spot Ether ETF is progressing smoothly. This announcement was made at the Bloomberg Invest Event.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 6:24 pm

BTAI

BioXcel Therapeutics Inc (NASDAQ:BTAI) announced positive topline results from a post-marketing study of Igalmi (dexmedetomidine) sublingual film, showing no evidence of tachyphylaxis, tolerance, or withdrawal. The study involved 28 inpatient adults with bipolar disorders or schizophrenia and demonstrated improvement in agitation symptoms with favorable safety results.

Portfolio Pulse from Vandana Singh

June 25, 2024 | 6:16 pm

LLY

NVO

A study published in JAMA Network Open reveals that Novo Nordisk's older weight-loss drug Saxenda (liraglutide) is associated with decreased bone mass density. The study raises concerns about similar effects in newer treatments like Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Portfolio Pulse from Vandana Singh

June 25, 2024 | 6:12 pm

ARWR

Arrowhead Pharmaceuticals is advancing its investigational drug Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial, following positive results from the Phase 2 MUIR study. The CAPITAN trial will focus on patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease. Arrowhead is also considering partnership options for the future development of Zodasiran.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 5:58 pm

AVGO

NVDA

Broadcom Inc (NASDAQ:AVGO) announced updates to its VMware Cloud Foundation, enhancing infrastructure modernization, developer productivity, and cybersecurity. Analysts highlight Broadcom's strong position in the AI semiconductor market, predicting significant revenue growth.

Portfolio Pulse from Anusuya Lahiri

June 25, 2024 | 5:58 pm